SEARCH

SEARCH BY CITATION

References

  • Aizenstein H, Nebes R, Saxton J, Price J, Mathis C, Tsopelas N, Ziolko S, James J, Snitz B, Houck P et al (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65: 1509-1517
  • Armitage S, (1946) An analysis of certain psychological tests used in the evaluation of brain injury. Psych Mono 60: 1-48
  • Bakkour A, Morris J, Dickerson B, (2009) The cortical signature of prodromal AD: regional thinning predicts mild AD dementia. Neurology 72: 1048-1055
  • Berg L, McKeel DW, Miller JP, Storandt M, Rubin EH, Morris JC, Baty J, Coats M, Norton J, Goate AM et al (1998) Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease—relation of histologic markers to dementia severity, age, sex, and apoE genotype. Arch Neurol 55: 326-335
  • Blennow K, Meyer GD, Hansson O, Minthon L, Wallin A, Zetterberg H, Lewczuk P, Vanderstichele H, Vanmechelen E, Kornhuber J et al (2009) Evolution of Abeta42 and Abeta40 Levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment. J Nutr Health Aging 13: 205-208
  • Braak H, Braak E (1997) Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18: 351-357
  • Cairns N, Ikonomovic M, Benzinger T, Storandt M, Fagan A, Shah A, Reinwald L, Carter D, Felton A, Holtzman D et al (2009) PiB-PET detection of cerebral Aβ may lag clinical, cognitive, and CSF markers of Alzheimer's disease: a case report. Arch Neurol (in press)
  • Cirrito J, May P, O'Dell M, Taylor J, Parsadanian M, Cramer J, Audia J, Nissen J, Bales K, Paul S et al (2003) In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-β metabolism and half-life. J Neurosci 23: 8844-8853
  • Craig-Schapiro R, Fagan A, Holtzman D, (2008) Biomarkers of Alzheimer's disease. Neurobiol Dis 35: 128-140
  • Dickerson B, Bakkour A, Salat D, Feczko E, Pacheco J, Greve D, Grodstein F, Wright C, Blacker D, Rosas H et al (2009) The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex 19: 497-510
  • Fagan A, Head D, Shah A, Marcus D, Mintun M, Morris J, Holtzman D, (2009) Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly. Ann Neurol 65: 175-183
  • Fagan A, Mintun M, Mach R, Lee S-Y, Dence C, Shah A, LaRossa G, Spinner M, Klunk W, Mathis C et al (2006) Inverse relation between in vivo amyloid imaging load and CSF Aβ42 in humans. Ann Neurol 59: 512-519
  • Fagan A, Roe C, Xiong C, Mintun M, Morris J, Holtzman D, (2007) Cerebrospinal fluid tau/Aβ42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64: 343-349
  • Fukumoto H, Tennis M, Locascio J, Hyman B, Growdon J, Irizarry M, (2003) Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol 60: 958-964
  • Gomez-Isla T, Price J, McKeel D, Morris J, Growdon J, Hyman B, (1996) Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 16: 4491-4500
  • Goodglass H, Kaplan E, (1983) Boston Naming Test scoring booklet, Philadelphia, Lea & Febiger
  • Gotz J, Chen F, Dorpe JV, Nitsch R, (2001) Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293: 1491-1495
  • Graff-Radford N, Crook J, Lucas J, Boeve B, Knopman D, Ivnik R, Smith G, Younkin L, Petersen R, Younkin S, (2007) Association of low plasma Aβ42/Aβ40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 64: 354-362
  • Grober E, Buschke H, Crystal H, Bang S, Dresner R, (1988) Screening for dementia by memory testing. Neurology 3: 900-903
  • Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L, (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5: 228-234
  • Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, Wallin A, Minthon L, Blennow K, (2008) Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging, in press, doi: 10.1016/j.neurobiolaging.2008.03.027
  • Hulette CM, Welsh-Bohmer KA, Murray MG, Saunders AM, Mash DC, McIntyre LM, (1998) Neuropathological and neuropsychological changes in “normal” aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol 57: 1168-1174
  • Jack C, Lowe V, Weigand S, Wiste H, Senjem M, Knopman D, Shiung M, Gunter J, Boeve B, Kemp B et al (2009) Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 132: 1355-1365
  • Klunk W, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt D, Bergström M, Savitcheva I, Huang G-F, Estrada S et al (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55: 306-319
  • Lachno D, Vanderstichele H, Groote GD, Kostanjevecki V, Meyer GD, Siemers E, Willey M, Bourdage J, Konrad R, Dean R, (2009) The influence of matrix type, diurnal rhythm and sample collection and processing on the measurement of plasma beta-amyloid isoforms using the Inno-Bia Plasma Abeta Forms Multiplex Assay. J Nutr Health Aging 13: 220-225
  • Lewczuk P, Kornhuber J, Vanmechelen E, Peters O, Heuser I, Maier W, Jessen F, Bürger K, Hampel H, Frölich L et al (2009) Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: a multicenter study with multiplexing. Exp Neurol (in press), PMID:19664622
  • Lewis J, Dickson D, Lin W, Chisholm L, A A AC, Jones G, Yen S, Sahara N, Skipper L, Yager D et al (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293: 1487-1491
  • Li G, Sokal I, Quinn J, Leverenz J, Brodey M, Schellenberg G, Kaye J, Raskind M, Zhang J, Peskind E et al (2007) CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 69: 631-639
  • Logan J, Fowler J, Volkow N, Wang G, Ding Y, Alexoff D, (1996) Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16: 834-840
  • Markesbery W, Schmitt F, Kryscio R, Davis D, Smith C, Wekstein D, (2006) Neuropathologic substrate of Mild Cognitive Impairment. Arch Neurol 63: 38-46
  • Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka S, Van der Flier WM, Blankenstein M, Ewers M et al (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302: 385-393
  • Mehta P, Pirttila T, (2005) Increased cerebrospinal fluid Abeta38/Abeta42 ratio in Alzheimer's disease. Neurodegener Dis 2: 242-245
  • Mintun M, LaRossa G, Sheline Y, Dence C, Lee S-Y, Mach R, Klunk W, Mathis C, DeKosky S, Morris J, (2006) [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67: 446-452
  • Morris J, McKeel D, Fulling K, Torack R, Berg L, (1988) Validation of clinical diagnostic criteria for Alzheimer's disease. Ann Neurol 24: 17-22
  • Morris J, Price J, (2001) Pathologic correlates of nondemented aging, mild cognitive impairment, and early stage Alzheimer's disease. J Mol Neurosci 17: 101-118
  • Morris J, Roe C, Grant E, Head D, Storandt M, Goate A, Fagan A, Holtzman D, Mintun M, (2009) PIB imaging predicts progression from cognitively normal to symptomatic Alzheimer's disease. Arch Neurol (in press)
  • Morris JC, (1993) The Clinical Dementia Rating (CDR). Current version and scoring rules. Neurology 43: 2412-2414
  • Oddo S, Caccamo A, Kitazawa M, Tseng B, LaFerla F, (2003a) Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 24: 1063-1070
  • Oddo S, Caccamo A, Shepherd J, Murphy M, Golde T, Kayed R, Metherate R, Mattson M, Akbari Y, LaFerla F, (2003b) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aß and synaptic dysfunction. Neuron 39: 409-421
  • Price J, Ko A, Wade M, Tsou S, McKeel D, Morris J, (2001) Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer's disease. Arch Neurol 58: 1395-1402
  • Price JL, Morris JC, (1999) Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease. Ann Neurol 45: 358-368
  • Rafii M, Aisen P, (2009) Recent developments in Alzheimer's disease therapeutics. BMC Med (in press)
  • Salloway S, Mintzer J, Weiner M, Cummings J, (2008) Disease-modifying therapies in Alzheimer's disease. Alzheimers Dement 4: 65-79
  • Schoonenboom N, Mulder C, Kamp GV, Mehta S, Scheltens P, Blankenstein M, Mehta P, (2005) Amyloid β 38, 40, and 42 species in cerebrospinal fluid: more of the same? Ann Neurol 58: 139-142
  • Schupf N, Tang M, Fukuyama H, Manly J, Andrews H, Mehta P, Ravetch J, Mayeux R, (2008) Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci USA 105: 14052-14057
  • Snider B, Fagan A, Roe C, Shah A, Grant E, Xiong C, Morris J, Holtzman D, (2009) Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol 66: 638-645
  • Sunderland T, Mirza N, Putnam K, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J et al (2004) Cerebrospinal fluid beta-amyloid -42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Biol Psychiatry 56: 670-676
  • Welge V, Fiege O, Lewczul P, Mollenhauer B, Esselmann H, Klafki H-W, Wolf S, Trenkwalder C, Otto M, Kornhuber J et al (2009) Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer's disease. J Neural Transm 116: 203-212